{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:13:40Z","timestamp":1783944820225,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102593","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:22:10Z","timestamp":1780503730000},"page":"102593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5653-999X","authenticated-orcid":false,"given":"Susu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Rao Gergal Gopalkrishna","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishw","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Homsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Kai","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10451","key":"10.1016\/j.clgc.2026.102593_bib0001","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clgc.2026.102593_bib0002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.clgc.2018.10.002","article-title":"Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study","volume":"17","author":"Saad","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"10.1016\/j.clgc.2026.102593_bib0003","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102593_bib0004","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2026.102593_bib0005","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clgc.2026.102593_bib0006","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10189","key":"10.1016\/j.clgc.2026.102593_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.clgc.2026.102593_bib0008","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102593_bib0009","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102593_bib0010","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102593_bib0011","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102593_bib0012","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN renal 101 trial","volume":"36","author":"Choueiri","year":"2025","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102593_bib0013","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102593_bib0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2025.09.006","article-title":"Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial","volume":"37","author":"Motzer","year":"2026","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102593_bib0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2026.102593_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2026.102593_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241257874","article-title":"Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials","volume":"16","author":"Zhou","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clgc.2026.102593_bib0018","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102593_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102380","article-title":"Do older patients with metastatic hormone-sensitive prostate cancer benefit from triplet or doublet therapy? A network meta-analysis","volume":"23","author":"Zhou","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2026.102593_bib0020","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102593_bib0021","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.clgc.2026.102593_bib0022","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2026.102593_bib0023","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clgc.2026.102593_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034626","article-title":"What is the optimum systemic treatment for advanced\/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis","volume":"10","author":"Cao","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.clgc.2026.102593_bib0025","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.21037\/apm-20-1884","article-title":"Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"6","key":"10.1016\/j.clgc.2026.102593_bib0026","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2021.03.016","article-title":"A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma","volume":"80","author":"Riaz","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102593_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102667","article-title":"Combination therapies in patients with favorable risk metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"122","author":"Bolek","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.clgc.2026.102593_bib0028","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.clgc.2022.07.002","article-title":"Does the time to start first-line treatment influence the survival of favorable-risk patients with metastatic renal cell carcinoma? Results of the MetaSurv-UroCCR 79 study","volume":"21","author":"Rolley","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102593_bib0029","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2217\/fon-2021-0888","article-title":"Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102593_bib0030","doi-asserted-by":"crossref","DOI":"10.1101\/2024.04.01.24305158","article-title":"Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials","volume":"3","author":"Sherry","year":"2024","journal-title":"BMJ Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:52:59Z","timestamp":1783943579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000935"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102593","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102593"}}